Navigation Links
A new class of anti-inflammatory drugs
Date:12/10/2008

This release is available in German.

In the treatment of pain, inflammation and fever, non-steroid anti-rheumatic drugs (NSAR) such as acetylsalicylic acid - more commonly known as Aspirin - or Ibuprofen have always been popular choices. However, had they been tested using today's stringent criteria, many of these drugs would not have passed the clinical trial stage, due to the potential risks and side effects they entail. This suggests the need for more innovative thinking in this area of drug therapy. One such new approach has been developed in Manfred Schubert-Zsilavecz's laboratory at the Goethe University, using chemical substances belonging to the dual mPGES-1/5-LO-Inhibitors. Oliver Werz's group at Tbingen has characterized the substances at the molecular/pharmacological level. Their research results now form the basis of a joint patent application, and a publication in the renowned "Journal of Medicinal Chemistry" (Koeberle et al, J Med Chem (2008), Nov 19. [Epub ahead of print]).

Aspirin and the related NSAR drugs act on the arachidonic acid biosynthesis cascade, which plays a central role in the onset of pain and inflammation. They thus prevent the synthesis of specific prostaglandins, which are essential for vital bodily functions. When the drugs are taken over a long period of time, the unselective inhibition of this essential pathway may result in unwanted side effects on the gastrointestinal tract and the cardiovascular system. As Schubert-Zsilavecz explains: "By comparison, our class of drugs/substances acts on a later stage in the arachidonate cascade, and is more selective. We therefore can expect it to have considerably fewer side effects."

A further advantage of this new class of drugs is that they not only specifically target the biosynthesis of prostaglandin, but also of leukotrienes, which are metabolites in the second important branch of the arachidonate cascade and play a central role in allergic and inflammatory reactions. This double attack promises more effective results for these new substances.

Gerd Geisslinger, Speaker of the LiFF-Initiative and President of the Center for Drug Research, Development and Safety (ZAFES) explains: "This is a most important success for our newly established Lipid Signalling Research Centre, which was established only a short time ago under the LOEWE initiative, funding research in the German state Hesse."


'/>"/>

Contact: Manfred Schubert-Zsilavecz
Schubert-Zsilavecz@pharmchem.uni-frankfurt.de
49-069-798-29339
Goethe University Frankfurt
Source:Eurekalert  

Related medicine news :

1. Popular class of diabetes drugs doubles risk of fractures in women
2. Triple-S Management Corporation Announces Conversion of Class A Shares and Commencement of Class B Stock Repurchase Program
3. Frost & Sullivan Recognises Best-in-Class Innovators
4. On Staying Alives 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador
5. Scientists at CSHL uncover new RNA processing mechanism and a new class of small RNAs
6. Foundation Radiology Group Adds World Class Cardiovascular Imaging Expert, Dr. Sanj Katyal, to Staff
7. Magistrate Judge Recommends Denial of Class Certification in Funeral Industry Antitrust Litigation
8. Alex Rodriguez, Ryan Howard and Terry Francona to Headline David Ortiz Celebrity Golf Classic
9. Avandias Heart Risk Higher Than Others in Its Class
10. Law Offices of Howard G. Smith Announces Class Action Lawsuit on Behalf of Investors of PharmaNet Development Group, Inc.
11. OmniVision Unveils 1.8 mm, Low Power Medical Sensor With Best-in-Class Low Light Performance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A new class of anti-inflammatory drugs
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps ... in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally ... one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... search for and donate to Give To Cure’s campaign that is crowdfunding clinical trials ... users make and share payments through a smart device. In 2015 alone, Venmo processed ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... DIEGO, Feb. 4, 2016  Aethlon Medical, Inc. ... affinity biofiltration devices to treat life-threatening diseases, today ... 2016 ended December 31, 2015. ... objectives set forth in our last quarterly call, ... reinforce our long-term objective to establish the Aethlon ...
Breaking Medicine Technology: